Investigational drug · Phase 3
ATSN-201
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for X-linked Retinoschisis.
Phase 3Last checked: Nov 19, 2026Latest source record: Sep 29, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "ATSN-201"
First trial start
2023
Aug 22, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "ATSN-201", any sponsor or status.
Conditions studied
As listed on its trial records.
- X-linked Retinoschisis
Approved drugs for the same conditions: Ophthalmology
Largest trials
Live from ClinicalTrials.gov: studies naming "ATSN-201" as an intervention, largest first.
- ATSN-201 Gene Therapy in RS1-Associated X-linked RetinoschisisPivotal-lookingRecruiting
Atsena Therapeutics Inc.Industry
NCT05878860 · 97 participants (planned) · Start Aug 22, 2023 · Primary completion Apr 2028
Drug: ATSN-201 · For: X-linked Retinoschisis
Sites: Phoenix, Arizona; La Jolla, California; Los Angeles, California · 21 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Laterally spreading AAV.SPR enables safe and efficient RS1 delivery to the macula after peripheral subretinal injection.
Andres-Mateos E, Kozlowski C, Zhang H, et al. · Mol Ther 2026
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.